Optimize vaccine immune response
Lonza’s proprietary Epibase® in silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in protein-based vaccine targets. The tool is driven by sequence information, structural bioinformatics and experimental data. The Epibase® in silico tool predicts potential peptide binding to HLA Class I and Class II molecules to drive a subsequent T cell response. In order to provide the optimal number of antigens that confer the broadest protection against infection, Epibase® in silico can identify conserved regions across several virus strains in order to help design vaccines for maximum coverage.
The Epibase® in silico tool supports lead candidate selection, ranking, optimization and rational design for the development of efficacious vaccines.
Help Increase Chance of Clinical Success
- 35 HLA Class I and 85 HLA Class II allotypes are represented
- Analysis includes binding affinity, promiscuity and frequency of allotypes
- High accuracy of prediction based on in vitro correlations
- Enhance immune response with in silico-guided engineering of epitope sequences
- Lonza can link in silico results with Epibase® in vitro assays for confirmation of promising vaccine candidates
Save Time and Money in Development
- Lonza's scientific experts perform the work, analyze results and provide consultation on data interpretation
- Rapidly assess vaccine candidates with a high throughput process
- Streamline candidate selection using in silico screening to select the most suitable candidates before proceeding to in vitro screening
- Focus R&D resources on a smaller number of vaccine candidates with the greatest chance of success early in development